Figure S1 - Image preprocessing

Before feature extraction, several steps were involved to preprocess images: (1) use threshold to exclude voxels that didn't have an intensity within the range of (mean-standard deviation, mean+8*standard deviation), to remove the noise; (2) normalize images using z-score normalization with z=100; (3) resample images to 1*1*1 mm³; (4) discretize images by a fixed bin width of 5. Below image shows the distribution of intensity range of each patient after completing image preprocessing. The intensity range had a mean of 710 and standard deviation of 203.




Figure S2. Feature repeatability of different DCE-MRI phases.

The repeatability of extracted radiomics features was assessed by single rater intraclass correlation coefficient (ICC) (1,1). The ICC for each feature was calculated under 30-time perturbations which involved random translation, rotation, as well as contour randomization. The formula for ICC calculation is:

$$\frac{MS_R - MS_W}{MS_R + (k+1)MS_W}$$

where MS_R is the mean square for all the features, MS_W is the mean square for the residual sources of variance, and k is the number of measurements. The calculation of ICC was performed using python package pingouin (version 0.5.2). An ICC >= 0.9 was determined as high-repeatable. Below figures shown the feature repeatability at different DCE-MRI phases.




Figure S3. Feature change across different DCE-MRI phases.

The assessment of feature change across different DCE-MRI phases involved evaluating whether the feature change calculated by subtraction was significantly different from zero. It was conducted by performiang a single-sample t test. A t test p value smaller than 0.05 was determined as 'change'. Below figures shown the feature change across different phases. The coordinate of x-axis n/m referred to feature change = feature at phase n – feature at phase m, and 0-5 denoted pre-contrast phase and 1^{st} to 5^{th} post-contrast phase.




Table S1. DCE-MRI parameters

Table 31. DCL-Wiki parameters	
Parameter	Value
Scanner Manufacturer	GE / Philips / SIEMENS
Magnetic Field Strength	1.5T / 3.0T
Fat Suppression	Required
Slice Orientation	Axial
Slice Thickness	0.8 - 3 mm
Pixel Size	0.3 - 1.4 mm
Slice Number	56 - 256
Repetition Time	3.8 - 9.3 s
Echo Time	1.3 - 4.8 s
Number of averages	0.7 - 3
Spacing Between Slices	0.8 - 2.6 mm
Flip Angle	10 - 20 degrees
Total Phase	6 - 11
Sequence Acquisition Time	80 - 100 s
Total Acquisition Time	At least 8 min after contrast agent injection


Table S2. Patient characteristics of pCR and non-pCR.

		non-pCR	pCR	P-value
Treatment	Paclitaxel	114	28	<0.001
	Paclitaxel + ABT 888 + Carboplatin	36	21	
	Paclitaxel + AMG 386	67	29	

positive 330 101	0.001 0.001
Paclitaxel + Ganitumab 69 20 Paclitaxel + MK-2206 32 14 Paclitaxel + MK-2206 + Trastuzumab 15 15 Paclitaxel + Neratinib 54 31 Paclitaxel + Pembrolizumab 29 25 Paclitaxel + Pertuzumab + Trastuzumab 13 20 Paclitaxel + Trastuzumab 17 3 T-DM1 + Pertuzumab 17 22 HR negative 201 153 positive 330 101 HER2 negative 432 169 positive 99 85 MP negative 312 94 positive 219 160	:0.001
Paclitaxel + MK-2206 32 14 Paclitaxel + MK-2206 + Trastuzumab 15 15 Paclitaxel + Neratinib 54 31 Paclitaxel + Pembrolizumab 29 25 Paclitaxel + Pertuzumab + Trastuzumab 13 20 Paclitaxel + Trastuzumab 17 3 T-DM1 + Pertuzumab 17 22 HR negative 201 153 positive 330 101 HER2 negative 432 169 positive 99 85 MP negative 312 94 positive 219 160	:0.001
Paclitaxel + MK-2206 + Trastuzumab 15 15 Paclitaxel + Neratinib 54 31 Paclitaxel + Pembrolizumab 29 25 Paclitaxel + Pertuzumab + Trastuzumab 13 20 Paclitaxel + Trastuzumab 17 3 T-DM1 + Pertuzumab 17 22 HR negative 201 153 < positive 330 101 HER2 negative 432 169 < positive 99 85 MP negative 312 94 < positive 219 160	:0.001
Paclitaxel + Neratinib 54 31 Paclitaxel + Pembrolizumab 29 25 Paclitaxel + Pertuzumab + Trastuzumab 13 20 Paclitaxel + Trastuzumab 17 3 T-DM1 + Pertuzumab 17 22 HR negative 201 153 positive 330 101 HER2 negative 432 169 positive 99 85 MP negative 312 94 positive 219 160	:0.001
Paclitaxel + Pembrolizumab 29 25 Paclitaxel + Pertuzumab + Trastuzumab 13 20 Paclitaxel + Trastuzumab 17 3 T-DM1 + Pertuzumab 17 22 HR negative positive 330 101 HER2 negative positive 432 169 < MP negative positive 312 94 < positive 219 160	:0.001
Paclitaxel + Pertuzumab + Trastuzumab 13 20 Paclitaxel + Trastuzumab 17 3 T-DM1 + Pertuzumab 17 22 HR	:0.001
Paclitaxel + Trastuzumab 17 3 17 22 17 22 18 17 22 19 160 19 19 19 19 19 19 19 1	:0.001
T-DM1 + Pertuzumab 17 22 HR negative 201 153 < positive 330 101 HER2 negative 432 169 < positive 99 85 MP negative 312 94 < positive 219 160	:0.001
HR negative positive 201 153 <	:0.001
positive 330 101 HER2 negative 432 169 < positive 99 85 MP negative 312 94 < positive 219 160	:0.001
HER2 negative positive 432 169 < MP negative positive 312 94 < positive 219 160	
positive 99 85 MP negative 312 94 < positive 219 160	
MP negative 312 94 < positive 219 160	0.001
positive 219 160	0.001
Age(mean range) 49 (23-77) 49 (25-73)	
Age(incul), unige) +3 (23 77) +3 (23 77)	0.53 <u>0</u>
Race American Indian or Alaska Native 3 1	0.791
American Indian or Alaska Native;White 0 1	
Asian 39 18	
Asian;White 3 1	
Black or African American 63 30	
Native Hawaiian or Pacific Islander 2 2	
Native Hawaiian or Pacific Islander;White 0 1	
White 419 199	
N/A 2 1	
Menopausal status Premenopausal 259 111	0.291
Perimenopausal 18 10	
Postmenopausal 152 89	
N/A 102 44	
Ethnicity Hispanic or Latino 66 38	0.573
Not Hispanic or Latino 464 216	
N/A 1 0	

Table S3 – Example of visualizing dynamic features

The table gives an example of how a dynamic feature quantify the change of a radiomics feature. The selected radiomics feature is original_glszm_LowGrayLevelZone_Emphasis. The dynamic feature is MD_hrv_classic_pnn40. It calculates the proportion of differences magnitude that is greater than 4% of standard deviation of the time series. In these figures, the x-axis denotes the phase of DCE-MRI and y-axis denotes the value of radiomics feature. And each line denotes one patient. Those have a relatively constant radiomics feature value after contrast agent injection (phase1 to phase5) were given lower dynamic feature value. This table also shows that patients with different dynamic feature value has d0i00fferent pCR rate.






Table S4 Performance of models with different feature number.

Dynamic model	Training AUC	Internal Validation	Radiomic model	Training AUC	Internal Validation
feature No.		AUC	feature No.		<u>AUC</u>
1	<u>0.571</u>	<u>0.560</u>	1	<u>0.595</u>	0.564
2	0.600	0.634	<u>2</u>	<u>0.621</u>	0.535
<u>3</u>	0.607	0.635	<u>3</u>	<u>0.650</u>	0.637
<u>4</u>	0.643	0.649	<u>4</u>	<u>0.650</u>	<u>0.640</u>
<u>5</u>	0.650	0.675	<u>5</u>	<u>0.650</u>	0.634
<u>6</u>	0.660	0.643	<u>6</u>	<u>0.650</u>	<u>0.635</u>
<u>7</u>	0.664	0.673	<u>7</u>	<u>0.666</u>	<u>0.603</u>
<u>8</u>	0.675	0.667	<u>8</u>	0.672	<u>0.603</u>
<u>9</u>	0.682	0.660	<u>9</u>	<u>0.673</u>	0.589
<u>10</u>	0.688	0.680	<u>10</u>	0.690	0.570
11*	<u>0.698</u>	<u>0.651</u>			

^{*}As the 10-feature dynamic model achieved the highest internal validation AUC. We further explored whether adding more dynamic features can obtain better performance. Therefore, the results of 11-feature dynamic model is also listed here.

Table S5 Odds ratios showing the significance of dynamic features in the dynamic model.

<u>Dynamic feature name</u>		
original firstorder RootMeanSquared SP Summaries welch rect centroid	1.098	
original firstorder Mean FC LocalSimple mean3 stderr	0.795	
original glrlm ShortRunLowGrayLevelEmphasis SP Summaries welch rect centroid	<u>0.807</u>	
original glszm GrayLevelNonUniformity CO HistogramAMI even 2 5	<u>0.780</u>	
original glszm LowGrayLevelZoneEmphasis MD hrv classic pnn40	<u>1.161</u>	
original glcm Id SB MotifThree quantile hh	<u>0.793</u>	
original glcm DifferenceEntropy CO HistogramAMI even 2 5	<u>1.193</u>	
original firstorder 90Percentile FC LocalSimple mean1 tauresrat	<u>1.248</u>	
original glcm Imc1 CO f1ecac	<u>0.868</u>	
original firstorder InterquartileRange DN HistogramMode 10	0.833	

Table S6 Odds ratios showing the significance of radiomic features in the radiomic model.

Radiomic feature name	Odds ratio
original_shape_Maximum2DDiameterColumn_phase0	0.793
original glcm Imc2 phase1	<u>1.345</u>
original glszm ZoneEntropy phase0	0.772
original ngtdm Busyness phase1	0.973

Table S7 Coefficients and p valus of variables in the CRD model

<u>Variable</u>	coefficient	<u>P value</u>
HR	<u>-1.076</u>	<0.001
HER2	0.837	<0.001
<u>Dynamic</u>	4.879	<0.001
Radiomic	4.169	< 0.001